Chardan Capital Markets analyst Geulah Liveshits raised the price target on Rocket Pharmaceuticals (NASDAQ: RCKT) to $33.00 (from $30.00) while ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Rocket Pharmaceuticals (RCKT) Prices 3.82M Share Common Offering at $22.25/ShDecember 11, 2019 5:59 AM Rocket Pharmaceuticals (RCKT) Announces Proposed Common Share OfferingDecember 10, 2019 4:02 PM Rocket Pharmaceuticals (RCKT) PT Raised to $42 at Oppenheimer Following Pipeline UpdateDecember 9, 2019 7:17 AM Rocket Pharmaceuticals (RCKT) Reports Preliminary Data from Phase 1/2 Trial of RP-L201 for Leukocyte Adhesion Deficiency-IDecember 9, 2019 7:02 AM Rocket Pharmaceuticals Announces Preliminary Data from Phase 1/2 Trial of RP-L201 for Leukocyte Adhesion Deficiency-IDecember 9, 2019 7:00 AM Rocket Pharmaceuticals (RCKT) Highlights Promising Preliminary Results from Phase 1 Trial of Commercial-Grade RP-L102 'Process B' for Fanconi AnemiaDecember 9, 2019 6:27 AM